CARNMT1

Across TCGA pan-cancer cohorts, CARNMT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CARNMT1 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CARNMT1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CARNMT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and OV are the cancer types where CARNMT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.785	0.214	.006	15	view →
UCEC	OS	Tertile	All	1.000	0.832	.008	12	view →
OV	DFS	Median	All	0.365	0.946	.025	8	view →
LUAD	DFS	Quartile	III,IV	0.775	0.277	.034	7	view →
CCRCC	DFS	Quartile	All	0.652	0.947	.014	4	view →
LSCC	DFS	Median	II,III,IV	0.821	0.566	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CARNMT1–PDAC (DFS)

Open the PDAC breakdown →